Paul Cairns

TL;DR: The identification of the second mutational event in 10 (43%) tumors establishes PTEN/MMAC1 as a main inactivation target of 10q loss in sporadic prostate cancer.

TL;DR: The results indicate that whereas DPC4 inactivation is prevalent in pancreatic carcinoma (48%), it is distinctly uncommon in the other tumor types examined.

TL;DR: It is found that small homozygous deletions represent the predominant mechanism of inactivation at 9p21 in bladder tumours and are present in other tumour types, including breast and prostate cancer.

TL;DR: The data suggest that inactivation of the p16 tumor suppressor gene is a frequent event in squamous cell carcinomas of the head and neck; p16 is inactivated by several distinct and exclusive events including homozygous deletion, point mutation, and promoter methylation; and immunohistochemical analysis for expression of thep16 gene product is an accurate and relatively simple method for evaluating p16 gene inactivation.

TL;DR: PTEN appears to be the major target of inactivation on chromosome 10q in glioblastoma multiforme, with loss of heterozygosity observed in 25 of 34 cases.